Consistent with this, a higher proportion of senescent-like CD8+ T cells in the BM and blood was associated with lower response rates to pembrolizumab sequenced after high-dose cytarabine in relapsed/refractory AML (7). The gene discussed is CD8A; the disease is acute myeloid leukemia.